Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Direct acting antiviral treatment of chronic hepatitis C in Denmark: factors associated with and barriers to treatment initiation

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

Sølund, C, Hallager, S, Pedersen, MS, Fahnøe, U, Ernst, A, Krarup, HB, Røge, BT, Christensen, PB, Laursen, AL, Gerstoft, J, Bélard, E, Madsen, LG, Schønning, K, Pedersen, AG, Bukh, J, Weis, N & Group, TDANHEP 2018, 'Direct acting antiviral treatment of chronic hepatitis C in Denmark: factors associated with and barriers to treatment initiation', Scandinavian Journal of Gastroenterology, bind 53, nr. 7, s. 849-856. https://doi.org/10.1080/00365521.2018.1467963

APA

Sølund, C., Hallager, S., Pedersen, M. S., Fahnøe, U., Ernst, A., Krarup, H. B., Røge, B. T., Christensen, P. B., Laursen, A. L., Gerstoft, J., Bélard, E., Madsen, L. G., Schønning, K., Pedersen, A. G., Bukh, J., Weis, N., & Group, T. DANHEP. (2018). Direct acting antiviral treatment of chronic hepatitis C in Denmark: factors associated with and barriers to treatment initiation. Scandinavian Journal of Gastroenterology, 53(7), 849-856. https://doi.org/10.1080/00365521.2018.1467963

CBE

Sølund C, Hallager S, Pedersen MS, Fahnøe U, Ernst A, Krarup HB, Røge BT, Christensen PB, Laursen AL, Gerstoft J, Bélard E, Madsen LG, Schønning K, Pedersen AG, Bukh J, Weis N, Group TDANHEP. 2018. Direct acting antiviral treatment of chronic hepatitis C in Denmark: factors associated with and barriers to treatment initiation. Scandinavian Journal of Gastroenterology. 53(7):849-856. https://doi.org/10.1080/00365521.2018.1467963

MLA

Vancouver

Author

Sølund, Christina ; Hallager, Sofie ; Pedersen, Martin S. ; Fahnøe, Ulrik ; Ernst, Anja ; Krarup, Henrik B. ; Røge, Birgit T. ; Christensen, Peer B. ; Laursen, Alex L. ; Gerstoft, Jan ; Bélard, Erika ; Madsen, Lone G. ; Schønning, Kristian ; Pedersen, Anders G. ; Bukh, Jens ; Weis, Nina ; Group, The DANHEP. / Direct acting antiviral treatment of chronic hepatitis C in Denmark: factors associated with and barriers to treatment initiation. I: Scandinavian Journal of Gastroenterology. 2018 ; Bind 53, Nr. 7. s. 849-856.

Bibtex

@article{338bfc150f1e419eaae38dd197293f53,
title = "Direct acting antiviral treatment of chronic hepatitis C in Denmark: factors associated with and barriers to treatment initiation",
abstract = "AbstractObjectives: We describe factors associated with and barriers to initiation of Direct Acting Antiviral (DAA) treatment in patients with chronic hepatitis C, who fulfill national fibrosis treatment guidelines in Denmark.Materials and Methods: In this nationwide cohort study, we included patients with chronic hepatitis C from The Danish Database for Hepatitis B and C (DANHEP) who fulfilled fibrosis treatment criteria. Factors associated with treatment initiation and treatment failure were determined by logistic regression analyses. Medical records were reviewed from patients who fulfilled fibrosis treatment criteria, but did not initiate DAA treatment to determine the cause.Results: In 344 (49%) of 700 patients, who fulfilled treatment criteria, factors associated with DAA treatment initiation were transmission by other routes than injecting drug use odds ratio (OR) 2.13 (CI: 1.38–3.28), previous treatment failure OR 2.58 (CI: 1.84–3.61) and ALT above upper limit of normal OR 1.60 (CI: 1.18–2.17). Th...",
keywords = "DAA,Direct Acting Antivirals,HCV,barriers to treatment,factors associated with treatment,hepatitis C virus,liver cancer,liver disease,treatment initiation",
author = "Christina S{\o}lund and Sofie Hallager and Pedersen, {Martin S.} and Ulrik Fahn{\o}e and Anja Ernst and Krarup, {Henrik B.} and R{\o}ge, {Birgit T.} and Christensen, {Peer B.} and Laursen, {Alex L.} and Jan Gerstoft and Erika B{\'e}lard and Madsen, {Lone G.} and Kristian Sch{\o}nning and Pedersen, {Anders G.} and Jens Bukh and Nina Weis and Group, {The DANHEP}",
year = "2018",
month = may,
day = "1",
doi = "10.1080/00365521.2018.1467963",
language = "English",
volume = "53",
pages = "849--856",
journal = "Scandinavian Journal of Gastroenterology",
issn = "0036-5521",
publisher = "Taylor & Francis",
number = "7",

}

RIS

TY - JOUR

T1 - Direct acting antiviral treatment of chronic hepatitis C in Denmark: factors associated with and barriers to treatment initiation

AU - Sølund, Christina

AU - Hallager, Sofie

AU - Pedersen, Martin S.

AU - Fahnøe, Ulrik

AU - Ernst, Anja

AU - Krarup, Henrik B.

AU - Røge, Birgit T.

AU - Christensen, Peer B.

AU - Laursen, Alex L.

AU - Gerstoft, Jan

AU - Bélard, Erika

AU - Madsen, Lone G.

AU - Schønning, Kristian

AU - Pedersen, Anders G.

AU - Bukh, Jens

AU - Weis, Nina

AU - Group, The DANHEP

PY - 2018/5/1

Y1 - 2018/5/1

N2 - AbstractObjectives: We describe factors associated with and barriers to initiation of Direct Acting Antiviral (DAA) treatment in patients with chronic hepatitis C, who fulfill national fibrosis treatment guidelines in Denmark.Materials and Methods: In this nationwide cohort study, we included patients with chronic hepatitis C from The Danish Database for Hepatitis B and C (DANHEP) who fulfilled fibrosis treatment criteria. Factors associated with treatment initiation and treatment failure were determined by logistic regression analyses. Medical records were reviewed from patients who fulfilled fibrosis treatment criteria, but did not initiate DAA treatment to determine the cause.Results: In 344 (49%) of 700 patients, who fulfilled treatment criteria, factors associated with DAA treatment initiation were transmission by other routes than injecting drug use odds ratio (OR) 2.13 (CI: 1.38–3.28), previous treatment failure OR 2.58 (CI: 1.84–3.61) and ALT above upper limit of normal OR 1.60 (CI: 1.18–2.17). Th...

AB - AbstractObjectives: We describe factors associated with and barriers to initiation of Direct Acting Antiviral (DAA) treatment in patients with chronic hepatitis C, who fulfill national fibrosis treatment guidelines in Denmark.Materials and Methods: In this nationwide cohort study, we included patients with chronic hepatitis C from The Danish Database for Hepatitis B and C (DANHEP) who fulfilled fibrosis treatment criteria. Factors associated with treatment initiation and treatment failure were determined by logistic regression analyses. Medical records were reviewed from patients who fulfilled fibrosis treatment criteria, but did not initiate DAA treatment to determine the cause.Results: In 344 (49%) of 700 patients, who fulfilled treatment criteria, factors associated with DAA treatment initiation were transmission by other routes than injecting drug use odds ratio (OR) 2.13 (CI: 1.38–3.28), previous treatment failure OR 2.58 (CI: 1.84–3.61) and ALT above upper limit of normal OR 1.60 (CI: 1.18–2.17). Th...

KW - DAA,Direct Acting Antivirals,HCV,barriers to treatment,factors associated with treatment,hepatitis C virus,liver cancer,liver disease,treatment initiation

U2 - 10.1080/00365521.2018.1467963

DO - 10.1080/00365521.2018.1467963

M3 - Journal article

C2 - 29720023

VL - 53

SP - 849

EP - 856

JO - Scandinavian Journal of Gastroenterology

JF - Scandinavian Journal of Gastroenterology

SN - 0036-5521

IS - 7

ER -

ID: 54945681